In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression
about
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanomaTumor-specific Th17-polarized cells eradicate large established melanomaB7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinomaMelanoma Peptide Vaccines.The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene productTumor antigens and tumor vaccines: peptides as immunogens.Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expressionAdvances in cancer vaccine development.Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway.Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responsesGenetically modified tumour vaccines: an obstacle race to break host tolerance to cancer.Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.The dendritic cell cytoskeleton promotes T cell adhesion and activation by constraining ICAM-1 mobilityLimited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phaseThe aging immune system and its relationship with cancerSurvivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.Molecular characterization of defective antigen processing in human prostate cancer.Combination approaches to potentiate immune response after photodynamic therapy for cancer.CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.A reassessment of the role of B7-1 expression in tumor rejection.Enhanced antitumor immunity in mice deficient in CD69.Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompT cells compete for access to antigen-bearing antigen-presenting cells.Tumor-infiltrating T lymphocytes: friends or foes?The central role of CD4(+) T cells in the antitumor immune response.Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1.Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity.Molecular profiling of tumor-specific TH1 cells activated in vivo.NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses.New treatment options for advanced pancreatic cancer.Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.Immunotherapy of MHC class I-deficient tumors.Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
P2860
Q24307739-4BFB5B3D-5B1D-438D-A98D-6DFC1D6E62A3Q24648032-3651CFEC-E977-46B1-86AA-56347BFEE933Q24676809-9CFA62A6-1546-4C76-B4B3-E6C3A328E36AQ30305778-B94EE451-13F6-457E-90F9-C4AB85ABE83BQ30453892-3801C121-3C10-4F32-A7CD-F581779C5B7CQ30469630-EB16AE95-4316-4AFE-9E21-52AA751878FEQ33366578-148A9993-517C-4750-8557-B3A076E43461Q33486534-FE4D4DDC-5710-468F-A349-EA4904996DFEQ33603404-B1D1CBD2-CE8E-4219-A44F-19ACAF50E3BDQ33713511-CE50B0C4-70CB-4BFE-BBBA-BC2BF2F08DB2Q33930126-4BDF60C0-6D1A-4A59-8E1F-DED61EDE8BB8Q34452039-F165BFAC-5064-4EC7-BB2C-131A6A27DA2EQ34544058-B5DDE7B0-C26C-4076-BB7F-4570BB488D2FQ34644359-CEA20B59-FFD2-4333-B961-FBC7C35E6EBEQ34769124-D83D5554-F6E2-4868-822D-A726CC91192EQ35094278-CD996931-BED3-409C-8173-94604E871844Q35407260-59370DA5-43DB-4C31-8652-1A81AD731A4FQ35569843-6C97AF49-0A7D-42E3-924A-4F2FE7CBB3AEQ35623772-E6E6A665-B41D-411E-8FED-27E411797901Q36093442-56C180B3-C63A-4C37-AC22-5A53CFE6F10EQ36183805-34342F37-2E97-4194-B557-8545200B983CQ36253709-1F4999FD-69B7-4194-A91A-0BA9EF96A252Q36284594-047058A9-7BEA-48A4-9B5D-6B2D5DC5B183Q36301801-8E8033C9-5804-411C-8752-99C5B062713AQ36365375-E52BDF9E-5756-42F2-B606-B4F136211AC2Q36370985-3AE34F70-69B6-48D7-A791-55E1116C88B2Q36371068-E2CD8F2A-5169-4F7D-B9F7-71FC7C0DDAE0Q36375152-990F6694-DA7A-4803-A0A0-04A4EFC022BCQ36376071-B1563E77-8395-418B-B515-0C7D9B3B82A4Q36381918-97569583-2042-4798-947B-A1108AB89BFBQ36401381-55D9E644-F639-417E-88C8-77A059FB4002Q36438003-DC25DD23-0ECD-4D8A-A9E4-37F777877ABFQ36438502-FDB965C4-D18A-4514-A41C-F69C8D2D179CQ36887852-222D98A5-F046-41D5-BBEE-2554C7B4FEBCQ37262370-7C0A7841-99DE-4C38-B57E-14CB7B5703BCQ37345841-DF386DA5-1BB3-4733-BDE9-06B03CE4F3CEQ37428061-FCCB98B6-4AA6-4DB3-81B1-EF46CA01AD93Q37785948-9A332ACD-0DDD-4256-8E53-B1E6DFB6FE3FQ37808218-BD88ADC1-467D-43B4-A23B-A65CDE65B59DQ37851180-E4379AAA-C51A-4685-AF0B-39D0E22F6778
P2860
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
In vivo priming of two distinc ...... role of MHC class I expression
@ast
In vivo priming of two distinc ...... role of MHC class I expression
@en
type
label
In vivo priming of two distinc ...... role of MHC class I expression
@ast
In vivo priming of two distinc ...... role of MHC class I expression
@en
prefLabel
In vivo priming of two distinc ...... role of MHC class I expression
@ast
In vivo priming of two distinc ...... role of MHC class I expression
@en
P2093
P2860
P356
P1476
In vivo priming of two distinc ...... role of MHC class I expression
@en
P2093
D M Pardoll
H I Levitsky
R J Hayashi
P2860
P304
P356
10.1084/JEM.179.4.1215
P407
P577
1994-04-01T00:00:00Z